GlassScriptPhysician profile
John S Tulloch
NPI 1740336486
$7,956.34
in general payments reported to CMS, 2019-2025
13 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,693 · 2020: $190 · 2021: $966 · 2022: $2,077 · 2023: $93.33 · 2024: $1,345 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,456 · Food and Beverage: $575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,456.18 |
| Food and Beverage | $574.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,001.49 | 2019-2024 | |
| Edwards Lifesciences Corporation | $2,497.32 | 2020-2025 | Sapien 3 Ultra Resilia, Evoque |
| Ancora Heart, INC. | $1,938.54 | 2022-2023 | Accucinch |
| Heartflow, INC. | $123.29 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.59 | 2019-2024 | Lifevest |
| Lantheus Medical Imaging, INC. | $82.86 | 2019-2025 | Definity |
| Merck Sharp & Dohme LLC | $50.79 | 2022 | |
| Pfizer INC. | $40.47 | 2022-2023 | |
| Atricure, INC. | $31.60 | 2019 | |
| Amgen INC. | $31.02 | 2019-2024 | Repatha |
| Cleerly, INC. | $28.73 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Abiomed | $24.03 | 2024 | Impella |
| Novartis Pharmaceuticals Corporation | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tulloch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.